FOXP3 and breast cancer: Moreover, treatment with pharmacological α- or β-AR blockers downregulates the expression of PD-L1 and forkhead box P3 (FOXP3), albeit to a lesser extent compared with tumor-specific sympathetic denervation, in human BC xenografts and in rats with chemically induced BCs 34.